The vaccine is produced in vero cells, allowing for automated production in bioreactors and simplifying scale up, according to Avir. The ease of scale up will allow Avir to modify production output inline with demand.
In addition, in deltaFLU the pathogenicity factor NS1 is deleted, resulting in the vaccine viruses being unable to replicate. Performing this step makes the vaccine very safe, according to Avir.
Austria-based Avir will conduct the Phase II trial at the Medical University of Vienna.